Research Reports

Summary

Nkarta reported a modest improvement in operating and net losses for Q1 FY2026, reflecting reduced cash burn from operating activities and disciplined capital allocation—though the company remains deeply unprofitable and continues to rely on equity financing to fund its clinical-stage NK cell platform.

Key takeaways

Operating income improved to -$30.9M (vs -$36.6M in Q1 FY2025), a 15.6% year-over-year narrowing driven by lower net cash outflows from operating assets and liabilities.

Net income was -$27.8M (vs -$32.0M in Q1 FY2025), with diluted EPS of $-0.37 (vs $-0.43), reflecting both the improved operating performance and lower non-cash adjustments.

Net cash used in operating activities was -$28.2M (vs -$29.6M in Q1 FY2025), aided by an increase in accounts payable and prepaid expenses and a decrease in operating lease liability.

Full analysis

Liquidity and Capital Resources

Operating Performance

Operating income for Q1 FY2026 was -$30.9 million, an improvement from -$36.6 million in Q1 FY2025. Net income was -$27.8 million, compared to -$32.0 million in the prior-year quarter, with diluted EPS of $-0.37 versus $-0.43. These improvements reflect a narrowing of losses across core metrics, though all remain deeply negative. The year-over-year improvement in operating income (15.6%) and net income (13.0%) is attributable to changes in operating assets and liabilities—not structural revenue generation or margin expansion.

NKTX · Nkarta, Inc.

Summary

Key takeaways

Full analysis

Liquidity and Capital Resources

Operating Performance

Cash Flow Drivers

Business Context and Outlook